![]() |
市场调查报告书
商品编码
1801181
血管成形术球囊市场规模、份额、趋势及预测(按产品类型、应用、材料、最终用户和地区),2025 年至 2033 年Angioplasty Balloons Market Size, Share, Trends and Forecast by Product Type, Application, Material, End User, and Region, 2025-2033 |
2024年,全球血管成形术球囊市场规模达25.2亿美元。展望未来, IMARC Group预测,到2033年,该市场规模将达到32亿美元,2025-2033年期间的复合年增长率为2.7%。目前,北美占据血管成形术球囊市场份额的主导地位,到2024年将超过39.2%。心血管疾病发病率上升、人口老化加剧、医疗技术进步以及对微创手术的需求不断增长,这些因素对市场产生了积极影响。这些因素共同推动了全球血管成形术球囊市场份额的提升。
血管成形术球囊市场成长的主要驱动因素之一是全球冠状动脉疾病和周边动脉疾病的盛行率不断上升。同时,老年人口的成长以及肥胖和高胆固醇人群的增加也推动了市场的成长。此外,药物涂层血管成形术球囊因其安全性和有效性,并能改善全身血流而广受欢迎。这也减少了可能导致血管破裂的血管植入物(例如支架)的使用。主要的促进成长的因素包括各种技术进步,从影像技术的发明到各种无需全身麻醉即可植入的改良球囊。其他预计将促进血管成形术球囊市场成长的因素包括消费者健康意识的增强、医疗基础设施的发展以及医学科学领域的广泛研发 (R&D)。
美国血管成形术球囊市场的需求受到心血管疾病(CVD)高发生率的影响,尤其是冠状动脉疾病,这类疾病需要血管成形术治疗。人口老化加剧,心臟病风险过高,进一步促进了市场的成长。此外,医疗技术的进步,例如药物洗脱和球囊扩张式血管成形术球囊的开发,也改善了治疗效果。例如,2025年1月,佛罗里达州一家医疗科技公司Concept Medical宣布其MAGICAL研究已招募首位患者,该研究比较了雷帕霉素涂层球囊与膝下外周动脉疾病(PAD)患者的标准血管成形术。此前,该公司已成功向美国食品药物管理局(FDA)申请MagicTouch经皮腔内血管成形术(PTA)的临床试验豁免(IDE)。该公司正在启动另外两项试验,以研究其药物涂层球囊取代传统经皮腔内血管成形术(PTA)。由于恢復时间更短、风险更低,人们对微创手术的偏好也推动了市场需求。强大的医疗基础设施、完善的报销政策以及领先的医疗器材製造商的存在,是支撑美国血管成形术球囊市场成长的关键趋势。
心血管疾病(CVD)盛行率不断上升
冠状动脉疾病(CAD)和周边动脉疾病(PAD)等心臟病病例的不断增加,正在影响血管成形术球囊的市场趋势。世界卫生组织(WHO)表示,心血管疾病是全球主要死亡原因,这增加了对血管成形术作为重要干预措施的需求。随着确诊心臟病且需要血管成形术的患者数量持续成长,对血管成形术球囊的需求也随之增加。
冠状动脉疾病(CAD)和周边动脉疾病(PAD)发病率的不断上升推动了血管成形术球囊市场的发展。世界卫生组织指出,心臟病是全球死亡的主要原因,这增加了对血管成形术的需求,使其成为有益的治疗方法。由于可透过血管成形术治疗的心臟病患者人数不断增加,对血管成形术球囊的需求也随之增加。
美国疾病管制与预防中心 (CDC) 于 2024 年 10 月报告称,约有 5% 的 20 岁及以上成年人患有冠状动脉疾病 (CAD),即每 20 人中约有 1 人患有此病。心臟病病例的上升趋势极大地促进了血管成形术球囊市场的扩张,因为越来越多的人选择透过血管成形术进行治疗。
FDA 批准和新技术
FDA 核准创新器械是血管成形术球囊市占率成长的主要驱动力。例如,波士顿科学公司的 AGENT 药物涂层球囊 (DCB) 为冠状动脉介入治疗开闢了新途径,特别适用于冠状动脉支架内再狭窄 (ISR) 患者。 2024 年 6 月,FDA 批准使用药物涂层球囊 (DCB) 支架进行血管成形术,这一里程碑已在改变临床实践,尤其是在俄亥俄健康医疗集团 (OhioHealth) 等机构。此外,位于宾州中部的 UPMC 心血管研究所于 2024 年 10 月为其首位患者采用了 FDA 最新批准的、专门针对 ISR 的 DCB 疗法。
这些治疗改进带来了更佳疗效,减少了血管再狭窄,甚至加快了患者的復原。新型球囊技术不断涌现,FDA 的审批范围也不断扩大,随着对精准微创冠状动脉介入治疗的需求不断增加,血管成形术球囊市场正在不断扩张。
老年人口增加和生活方式改变
人口老化趋势日益加剧,尤其是在亚太地区,这提升了血管成形术球囊市场的前景。随着老化,人们罹患心血管疾病的几率也随之上升,因此需要进行此类手术的次数也随之增加。此外,生活方式的改变和不良的饮食习惯也进一步加剧了心血管疾病的发生。吸烟、糖尿病、高血压等生活方式疾病风险因素的增加,进一步推动了全球对血管成形术治疗的需求。
根据联合国亚洲及太平洋经济社会委员会(UNESCAP)的数据,预计2023年,亚太地区老年人口(60岁以上)将达到6.97亿,约占全球老年人口的60%。由于心血管疾病的发生率随着年龄增长而增加,老年人口的增加将进一步增加对血管成形术介入治疗的需求,进而增加对血管成形术球囊的需求。
The global angioplasty balloons market size was valued at USD 2.52 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 3.20 Billion by 2033, exhibiting a CAGR of 2.7% during 2025-2033. North America currently dominates the angioplasty balloons market share by holding over 39.2% in 2024. The market is influenced positively by increasing cardiovascular diseases, rising aging population, advancements in medical technology, and growing demand for minimally invasive procedures. These factors, collectively, are aiding to increase the angioplasty balloons market share across the globe.
One of the major driving factors behind the angioplasty balloons market growth is the increasing prevalence of coronary and periphery artery diseases around the globe. In line with this, the growing geriatric population and people suffering from obesity and high levels of cholesterol also help the market growth. Additionally, drug-coated angioplasty balloons are very popular because they increase safety, and effectiveness and provide better blood flow through the body. It has also led to a reduction in the use of vessel implants, such as stents, that could cause vessel fracture. Major growth-inducing factors include diverse technological advancements ranging from the invention of imaging technologies to various modified variants that may be implanted without general anesthesia. Other factors expected to aid the angioplasty balloons market growth include increasing health consciousness among consumers, the development of healthcare infrastructure, and extensive research and development (R&D) in medical sciences.
The angioplasty balloons market demand in the United States is influenced by the high incidence of cardiovascular diseases (CVDs), particularly coronary artery disease, which requires angioplasty procedures for treatment. The aging population, with an excessive risk of heart-related conditions, further contributes to market growth. Moreover, advancements in medical technology, such as the development of drug-eluting and balloon-expandable angioplasty balloons, improve treatment outcomes. For instance, in January 2025, Concept Medical, a Florida healthtech company, announced the enrollment of the first patient in its MAGICAL study, which compares a balloon coated with sirolimus to standard angioplasty for patients with peripheral artery disease (PAD) below the knee. The announcement follows the company's successful application for an Investigational Device Exemption (IDE) for the MagicTouch PTA from the US Food and Drug Administration (FDA). Two more trials are being initiated by the business to investigate its drug-coated substitute for conventional percutaneous transluminal angioplasty (PTA). The inclination for minimally invasive procedures due to shorter recovery times and reduced risks also drives market demand. Robust healthcare infrastructure, well-established reimbursement policies, and the existence of leading medical device manufacturers represent the key angioplasty balloons market trends supporting the growth of the market in the U.S.
Increasing Prevalence of Cardiovascular Diseases (CVDs)
The rising cases of heart diseases, such as CAD and PAD, are influencing the angioplasty balloons market trends. Cardiovascular diseases are the leading cause of death globally, according to the WHO, which has amplified the demand for angioplasty as an essential intervention. As the number of patients diagnosed with heart conditions that require angioplasty continues to grow, the demand for angioplasty balloons rises in tandem.
The angioplasty balloons market is propelled by the increasing incidence of CAD and PAD. Cardiac diseases are the primary cause of mortality in the world as per WHO which has increased the need for angioplasty as one of the beneficial treatments. Since the patient population with heart conditions that can be treated through angioplasty is increasing, so is the need for angioplasty balloons.
According to the Centers for Disease Control and Prevention (CDC), which reported in October 2024 that approximately 5% of adults aged 20 and above suffer from coronary artery disease (CAD), this is roughly 1 in 20 individuals. This upward trend in heart disease cases contributes immensely to the expansion of the market for angioplasty balloons since more people opt for treatment through angioplasty procedures.
FDA Approvals and New Technologies
The FDA approval of innovative devices is a major growth driver in the angioplasty balloons market share. For instance, Boston Scientific's AGENT Drug-Coated Balloon (DCB) has opened new avenues for the treatment of coronary interventions, especially for patients with coronary in-stent restenosis (ISR). In June 2024, the FDA approved the employment of drug-coated balloon (DCB) stents for angioplasty procedures, a milestone that is already transforming clinical practices, particularly at institutions like OhioHealth. In addition, the UPMC Heart and Vascular Institute in Central Pennsylvania treated its first patient with newly FDA-approved DCB therapy intended specifically to target ISR in October 2024.
Such improvements in treatments have better results, decrease restenosis, and even hasten patients' recovery. Ongoing novel balloon technologies continue to emerge, in addition to enlarging FDA clearances, where the market of angioplasty balloons is in its way toward expansion with greater demands for proper and less-invasive coronary intervention.
Rising Geriatric Population and Lifestyle Changes
The growing age population, predominantly in Asia and the Pacific region, is enhancing the angioplasty balloons market outlook. With ageing, people fall prey to greater cardiovascular diseases due to which higher numbers of such procedures are necessary. This combined with lifestyle changes and undesirable dietary habits further precipitates more cardiovascular illness. The increased emissions of risk factors for lifestyle diseases including smoking, diabetes, and hypertension among others is further driving the demand for angioplasty treatments across the globe.
According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), in 2023, an estimated 697 million older individuals (aged 60 and above) live in the region, accounting for about 60% of the world's elderly population. This increasing number of elderly people will further increase the demand for angioplasty interventions and, consequently, angioplasty balloons, as the incidence of cardiovascular conditions increases with age.
Normal Balloons leads the market with around 54.8% of the market share in 2024. Normal balloons hold the largest share in the angioplasty balloons market because of their extensive use, proven efficacy, and affordability when compared to more specialized options like drug-eluting balloons. These balloons are frequently employed to widen constricted or obstructed arteries during routine angioplasty treatments, and they frequently produce dependable outcomes. Healthcare practitioners appreciate them because of their ease of use, simplicity, and track record of success in routine treatments. Additionally, a wider variety of healthcare facilities can use regular balloons due to their lower cost, particularly in developing nations with tight budgets.
Coronary Angioplasty leads the market with around 55.6% of the market share in 2024. Coronary angioplasty holds the largest share in the angioplasty balloons market owing to the high prevalence of coronary artery diseases (CAD), which require intervention to restore blood flow to the heart. As CAD remains a leading cause of death globally, coronary angioplasty is a widely performed procedure. Coronary angioplasty is growing fast as it's a quicker, lower-risk way to treat heart blockages compared to other surgical options. New technology in angioplasty balloons with drug-release capabilities makes this procedure even more successful and popular.
Nylon's exceptional strength, flexibility, and durability are projected to contribute to its substantial market share in the angioplasty balloon industry. Because of its great tensile strength, balloons that can tolerate the pressures needed for angioplasty treatments can be produced. Additionally, nylon is very biocompatible, which makes it appropriate for prolonged bodily use. Its extensive use in the production of balloon catheters is also a result of its affordability and ease of processing.
The market for angioplasty balloons favors polyurethane because of its exceptional biocompatibility, flexibility, and durability. It ensures optimal performance during angioplasty treatments by enabling precise balloon inflation and offering exceptional compliance. For catheter balloons used in cardiac procedures, polyurethane is ideal because of its capacity to retain shape integrity at high pressure. Its exceptional strength-to-weight ratio and adaptable qualities further encourage its use in the medical device sector.
Silicone urethane co-polymers are preferred in the production of angioplasty balloons because of their superior strength, flexibility, and biocompatibility. During treatments, their exceptional flexibility and kink resistance provide dependable balloon expansion and ideal vascular dilatation. Additionally, these co-polymers provide a smooth surface, which lowers friction and lowers the possibility of issues. They are perfect for medical applications like angioplasty because of their great resistance to wear and tear and capacity to function well under pressure.
Ambulatory Surgery Centers leads the market with around 32% of the market share in 2024 because they excel at delivering minimally invasive surgical services at lower costs with high efficiency. ASCs are popular with both patients and healthcare workers because their treatment costs are lower, patients don't stay in the hospital for long, and they recover faster. Due to the rising incidence of coronary artery diseases and the need for outpatient treatment, ASCs are increasingly performing angioplasty operations. Furthermore, angioplasty balloons and other technological and equipment developments have made it possible for ASCs to perform these procedures with extreme safety and precision, which has further increased their market domination.
Regional Analysis
In 2024, North America accounted for the largest market share of over 39.2%. The increased prevalence of cardiovascular diseases (CVDs), such as coronary artery disease, which requires angioplasty operations, is plunging the market for angioplasty balloons in North America. Demand is further enhanced by an older population that has a higher prevalence of heart-related illnesses. The extensive use of minimally invasive procedures and sophisticated healthcare infrastructure both support market expansion. Furthermore, treatment results are improved by the availability of cutting-edge angioplasty balloon technology, such as drug-eluting balloons. The presence of leading medical device manufacturers in North America, government healthcare initiatives, and high healthcare spending all contribute to the market's growth.
United States Angioplasty Balloons Market Analysis
In 2024, the United States accounted for the largest market share of over 90.00% in North America. Heart disease remains the leading cause of death across the United States, cutting across men and women from all racial and ethnic backgrounds. In October 2024, it was reported that someone dies from cardiovascular disease every 33 seconds in the United States. This number is very high and reflects the heavy burden that heart disease has on public health, which will continue to create a need for successful cardiovascular therapies like angioplasty procedures.
The study revealed that a study appeared in February 2023 in the Journal of the American College of Cardiology, which proved that the incidence rate of ASCVD is considerably higher in patients who have risk predictions with the 10-year and 30-year being elevated, and this rate goes up to as high as 2.60 per 1,000 person-years in at-risk individuals. This increasing incidence of cardiovascular disease, particularly among those at higher risk, is likely to fuel the demand for angioplasty treatments, thereby driving growth in the U.S. angioplasty balloons market. The continuous requirement for interventional procedures to treat atherosclerosis supports the growing market for angioplasty balloons in the region.
Europe Angioplasty Balloons Market Analysis
A rising number of heart and circulatory diseases in Europe is one of the main drivers for the angioplasty balloons market. Around 7.6 million people in the UK suffered from heart and circulation disorders in 2021, with 4 million males and 3.6 million women afflicted, according to research released in July 2022 by the British Heart Foundation. This growing burden of cardiovascular conditions puts an imperative to develop more effective treatments like angioplasty. Angioplasty is the common procedure in restoring blood flow to blocked arteries.
Because there is an age increase in populations and more incidences of the disease, especially heart disease, demand for balloons in angioplasty is on the rise. There is going to be even greater emphasis put on cardiovascular diseases with the improvement of medical and advanced technologies within Europe, where there will consequently be increased applications of angioplasty balloons in treatment services. The area is expected to see growth throughout the forecasted period due to the higher level of heart diseases and the involvement of interventional care.
Asia Pacific Angioplasty Balloons Market Analysis
The main driving factor for the angioplasty balloons market in the Asia Pacific region is the growing number of CVD cases. According to an NCBI report in 2023, "There were about 330 million cases of CVD in China, which includes 13 million strokes, 11.39 million coronary heart disease, 8.9 million heart failure cases, and pulmonary heart disease in 5 million people". This heavy burden on cardiovascular health doubles the requirement of interventions such as angioplasty.
As the region becomes increasingly urbanized, and demographic changes become rampant, more individuals are becoming victimized by various cardiovascular treatments like angioplasty. High and widespread prevalence of CVD is expected to make the region flourish in the next few years due to advancements in the balloon technology associated with angioplasty. High patient demands of coronary and peripheral artery treatment further increase the future market size for angioplasty balloons.
Latin America Angioplasty Balloons Market Analysis
Cardiovascular diseases (CVD) are the leading cause of death in Mexico, accounting for about 20% of total deaths, with ischemic heart disease (IHD) responsible for 68.5% of these deaths, according to the NIH in 2019. This high prevalence of heart disease in the region is a significant driver for the Latin American angioplasty balloons market. As the burden of cardiovascular conditions continues to rise, the demand for effective treatments, including angioplasty procedures, is increasing.
The increasing prevalence of ischemic heart disease and other CVDs in Mexico and other Latin American countries is fueling the demand for angioplasty balloon technologies. The increasing number of patients requiring interventions to treat CAD and PAD is a strong growth opportunity for the market. Angioplasty balloons are also enhancing patient outcomes and, therefore their demand in this region is accelerated. This development is likely to propel the sector growth in Latin America's Angioplasty Balloons market.
Middle East and Africa Angioplasty Balloons Market Analysis
According to the report from BMC Cardiovascular Disorders, in 2021, the United Arab Emirates had the highest age-standardized prevalence rate of cardiovascular diseases, with 11,066.8 cases per 100,000 people. In the same year, the age-standardized incidence rate of CVD was highest in the Syrian Arab Republic. Such alarming statistics show the rising burden of heart diseases in the MEA region, which further increases the demand for angioplasty procedures and, consequently, angioplasty balloons.
The increasing incidence and prevalence of cardiovascular diseases such as CAD and PAD are promoting interventional therapy. Angioplasty balloons are an essential component of these therapies, which try to reestablish blood flow in diseased arteries. As the medical infrastructure improves and knowledge about CVD increases, the MEA angioplasty balloons market is projected to grow highly. Advances in balloon technologies, including drug-coated balloons, are also contributing to better treatment outcomes, further supporting market growth in the region.
The angioplasty balloons market is highly competitive, with key players such as Boston Scientific, Medtronic, Abbott Laboratories, and Terumo Corporation dominating the industry. Product innovation includes drug-eluting balloons, bioresorbable balloons, and next-generation technology to improve the nature of the clinical outcomes these companies offer. As companies attempt to expand their product portfolio and global reach, strategic collaborations, mergers, and acquisitions are general. Other emerging players also are gaining traction by selling cost-effective solutions, despite striking underserved markets. Regulatory approval and adherence to strict quality standards are critical for maintaining a competitive edge in this growing market.